Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice

被引:74
|
作者
Bogorad, Roman L. [1 ]
Yin, Hao [1 ]
Zeigerer, Anja [2 ]
Nonaka, Hidenori [2 ]
Ruda, Vera M. [1 ]
Zerial, Marino [2 ]
Anderson, Daniel G. [1 ,3 ,4 ,5 ]
Koteliansky, Victor [1 ,6 ]
机构
[1] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
[2] Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany
[3] MIT, Dept Chem Engn, Cambridge, MA 02139 USA
[4] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA
[5] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA
[6] Skolkovo Inst Sci & Technol, Skolkovo 143025, Russia
来源
NATURE COMMUNICATIONS | 2014年 / 5卷
关键词
BREAST-CANCER CELLS; IN-VIVO; ALPHA(V) INTEGRINS; INDUCED APOPTOSIS; MOUSE-LIVER; RAT-LIVER; GENE; ACTIVATION; EXPRESSION; BETA(1);
D O I
10.1038/ncomms4869
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Integrins play an important role during development, regulating cell differentiation, proliferation and survival. Here we show that knockdown of integrin subunits slows down the progression of hepatocellular carcinoma (HCC). Using nanoparticulate delivery of short interfering RNAs targeting beta 1 and alpha v integrin subunits, we downregulate all integrin receptors in hepatocytes. Short-term integrin knockdown (2 weeks) does not cause apparent structural or functional perturbations of normal liver tissue. Alterations in liver morphology accumulate on sustained integrin downregulation (7 weeks). The integrin knockdown leads to significant retardation of HCC progression, reducing proliferation and increasing tumour cell death. This tumour retardation is accompanied by reduced activation of the MET oncogene as well as expression of its mature form on the cell surface. Our data suggest that transformed proliferating cells from HCC are more sensitive to knockdown of integrins than normal quiescent hepatocytes, highlighting the potential of small interfering RNA-mediated inhibition of integrins as an anti-cancer therapeutic approach.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice
    Roman L. Bogorad
    Hao Yin
    Anja Zeigerer
    Hidenori Nonaka
    Vera M. Ruda
    Marino Zerial
    Daniel G. Anderson
    Victor Koteliansky
    Nature Communications, 5
  • [2] Biodistribution and Metabolism Studies of Lipid Nanoparticle-Formulated Internally [3H]-Labeled siRNA in Mice
    Christensen, Jesper
    Litherland, Karine
    Faller, Thomas
    van de Kerkhof, Esther
    Natt, Francois
    Hunziker, Juerg
    Boos, Julien
    Beuvink, Iwan
    Bowman, Keith
    Baryza, Jeremy
    Beverly, Mike
    Vargeese, Chandra
    Heudi, Olivier
    Stoeckli, Markus
    Krauser, Joel
    Swart, Piet
    DRUG METABOLISM AND DISPOSITION, 2014, 42 (03) : 431 - 440
  • [3] Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model
    Linder, Benedikt
    Weirauch, Ulrike
    Ewe, Alexander
    Uhmann, Anja
    Seifert, Volker
    Mittelbronn, Michel
    Harter, Patrick N.
    Aigner, Achim
    Koegel, Donat
    CANCERS, 2019, 11 (03):
  • [4] Targeting integrins in hepatocellular carcinoma
    Wu, Yanhua
    Qiao, Xiaojing
    Qiao, Shouyi
    Yu, Long
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (04) : 421 - 437
  • [5] Targeting Cancer Chemotherapy Resistance by Precision Medicine-Driven Nanoparticle-Formulated Cisplatin
    Siemer, Svenja
    Bauer, Tobias A.
    Scholz, Paul
    Breder, Christina
    Fenaroli, Federico
    Harms, Gregory
    Dietrich, Dimo
    Dietrich, Jorn
    Rosenauer, Christine
    Barz, Matthias
    Becker, Sven
    Strieth, Sebastian
    Reinhardt, Christoph
    Fauth, Torsten
    Hagemann, Jan
    Stauber, Roland H.
    ACS NANO, 2021, 15 (11) : 18541 - 18556
  • [6] siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells
    Liu, Wensong
    Zhu, Feng
    Jiang, Yong
    Sun, Donglin
    Yang, Bo
    Yan, Haijiao
    ONCOLOGY REPORTS, 2013, 29 (03) : 1183 - 1188
  • [7] siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo
    Raskopf, Esther
    Vogt, Annabelle
    Sauerbruch, Tilman
    Schrnitz, Volker
    JOURNAL OF HEPATOLOGY, 2008, 49 (06) : 977 - 984
  • [8] Targeting WDxR motif reprograms immune microenvironment and inhibits hepatocellular carcinoma progression
    Zhang, Heng
    Chen, Gang
    Feng, Xing
    Song, Huiwen
    Meng, Lingbing
    Fu, Yao
    Yang, Jun
    Fan, Zhiwen
    Ding, Youxiang
    Du, Zhijie
    Wang, Jianchao
    Yang, Li
    Zhang, Jun
    Sun, Lixia
    Liu, Zhigang
    Zhang, Zhiyong
    Li, Quanhai
    Fan, Xiangshan
    EMBO MOLECULAR MEDICINE, 2023, 15 (05)
  • [9] siRNA TARGETING Robo1 INHIBITS HEPATOCELLULAR CARCINOMA GROWTH AND TUMOR ANGIOGENESIS IN VIVO
    Yingjie, L.
    Lvzhen, H.
    Shu, L.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S203 - S203
  • [10] In vivo target validation in orthotopic hepatocellular carcinoma model using formulated siRNA
    Liao, Baisong
    Kellner, Debra
    Wang, Chunrong
    Wu, Shilu
    Molina, Marion
    Zhu, De-Min
    Gollerkeri, Ashwin
    Pachuk, Catherine
    CANCER RESEARCH, 2011, 71